Title
Developmental aspects of FXAND in a man with the FMR1 premutation.

Permalink
https://escholarship.org/uc/item/60r0v4qr

Journal
Molecular genetics & genomic medicine, 8(2)

ISSN
2324-9269

Authors
Santos, Ellery
Emeka-Nwonovo, Chinelo
Wang, Jun Yi
et al.

Publication Date
2020-02-01

DOI
10.1002/mgg3.1050

Peer reviewed
CLINICAL REPORT

Developmental aspects of FXAND in a man with the FMR1 premutation

Ellery Santos1,2 | Chinelo Emeka-Nwonovo1 | Jun Yi Wang1,3,4 | Andrea Schneider1,2 | Flora Tassone1,4 | Paul Hagerman1,4 | Randi Hagerman1,2

1MIND Institute, University of California Davis School of Medicine, Sacramento, CA, USA
2Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA
3Center for Mind and Brain, University of California Davis, Sacramento, CA, USA
4Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA, USA

Correspondence
Randi Hagerman, MIND Institute UCDMC, 2825 50th Street, Sacramento, California, 95817
Email: rjhagerman@ucdavis.edu

Funding information
National Institute of Child Health and Human Development, Grant/Award Number: HD036071 and U54 HD079125

Abstract

Background: Fragile X mental retardation 1 (FMR1) premutation can cause developmental problems including autism spectrum disorder (ASD), social anxiety, depression, and attention deficit hyperactivity disorder (ADHD). These problems fall under an umbrella term of Fragile X-associated Neuropsychiatric Disorders (FXAND) and is separate from Fragile X-associated Tremor/Ataxia syndrome (FXTAS), a neurodegenerative disorder.

Methods/Clinical Case: A 26-year-old Caucasian male with the Fragile X premutation who presented with multiple behavior and emotional problems including depression and anxiety at 10 years of age. He was evaluated at 13, 18, and 26 years old with age-appropriate cognitive assessments, psychiatric evaluations, and an MRI of the brain.

Results: The Autism Diagnostic Observation Scale (ADOS) was done at 13 years old and showed the patient has autism spectrum disorder (ASD). An evaluation at 18 years old showed a full-scale IQ of 64. A Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) performed at 26 years old confirmed the previous impression of social anxiety disorder, agoraphobia disorder, and selective mutism. His MRI acquired at 26 years old showed enlarged ventricles, increased frontal subarachnoid spaces, and hypergyrification.

Conclusion: This is an exemplary case of an FMR1 premutation carrier with significant psychiatric and cognitive issues that demonstrates Fragile X-associated Neuropsychiatric Disorders (FXAND) as separate from the other well-known premutation disorders.

KEYWORDS
ASD, FMR1, Fragile X, FXAND, Premutation

1 | INTRODUCTION

Most individuals with the premutation (55 to 200 CGG repeats) in the Fragile X Mental Retardation 1 gene (FMR1, OMIM: 309,550) do not have intellectual disability in contrast to those with Fragile X Syndrome (FXS) that is caused by the full mutation (>200 CGG repeats) in FMR1. However, those with the premutation often have other problems including the...
Fragile X-associated Primary Ovarian Insufficiency (FXPOI) before age 40, seen in approximately 20% of female carriers; and the Fragile X-associated Tremor/Ataxia syndrome (FXTAS), a neurodegenerative disorder, seen in approximately 45% of male and 16% of female carriers with the premutation after age 50 (Hagerman & Hagerman, 2016). The cause of these clinical problems is related to the elevated FMR1-mRNA that correlates positively with the increase in CGG repeat number in the premutation range. The elevated mRNA can be toxic to the cell and is associated with sequestration of vital proteins important for neuronal functions, mitochondrial dysfunction, calcium dysregulation, and chronic DNA damage repair (Hagerman & Hagerman, 2016).

The premutation can also cause developmental problems including social deficits, autism spectrum disorder (ASD), social anxiety, depression, obsessive compulsive disorder, and attention deficit hyperactivity disorder (ADHD) (Chonchaiya et al., 2012; Farzin et al., 2006). These problems in addition to adult disorders such as chronic fatigue, central pain syndrome, migraines, and autoimmune dysfunction fall under an umbrella term of Fragile X-associated Neuropsychiatric Disorders (FXAND). At least one of these problems occurs in the majority of premutation carriers. Bailey, Raspa, Olmsted, and Holiday (2008) found developmental problems in about 30% of premutation carriers. These problems are related to mRNA toxicity and mitochondrial deficits documented in children with psychiatric problems and the premutation (Napoli et al., 2018; Song et al., 2016). Premutation neurons in culture have higher rates of spikes and they also die faster in culture compared to neurons without the premutation (Chen et al., 2009). In addition, GABA deficits have been documented in premutation carriers (Conde et al., 2013; D’Hulst et al., 2006).

The prevalence of the premutation is approximately 1 in 200 girls and 1 in 400 boys from newborn screening in the US (Tassone et al., 2012). However, in other countries the premutation prevalence may be much higher, such as Colombia, Israel and Mallorca (Saldarriaga et al., 2018). The prevalence of ASD in premutation males depends on whether they are the proband of the family who presents to a developmental center or whether they are identified by cascade testing (non-proband) once another family member demonstrates an FMR1-mutation. In the study by Chonchaiya et al. (2012), of 50 boys with the premutation, 68% of the probands had ASD whereas 28% of the non-probands had ASD and none of the controls had ASD. Overall 14% of the boys with the premutation had seizures and the presence of seizures was highly correlated with ASD (Chonchaiya et al., 2012). Although most of the boys in these studies had a normal IQ, a subgroup had mild intellectual disability (Chonchaiya et al., 2012).

Here we report a patient with the premutation who has been followed clinically from childhood into adulthood to demonstrate the trajectory of FXAND symptoms over time.

2 | CASE PRESENTATION

The patient is a 26-year-old Caucasian male with the Fragile X premutation documented via FMR1 (GenBank: NG_007529.2) DNA testing who has been diagnosed with selective mutism, agoraphobia, and social anxiety disorder initially presented at 13 years of age. His CGG repeat size was 56, while his FMR1 mRNA was 2.09 (± 0.12) times normal. He was born full-term after an uneventful pregnancy. He did not require resuscitation and did well in the newborn period.

Early milestones were appropriate; he sat at 6 months, began crawling at 8 months and walking at 13 months. At 18 months he was saying 4 words but regressed and lost his ability to speak. During this time, he received speech and language therapy and by the age of 4 he began to speak with words again. By 6 years of age he was speaking spontaneously in sentences. Initially he was diagnosed with dyspraxia. However, he had a history of selective mutism particularly when seeing new people or in visiting physicians. He has several autistic features including poor eye contact, perseverations, tantrums, and tactile defensiveness. He is also very sound sensitive and chews on his nails excessively. He had problems falling asleep at night which has been attributed to poor sleeping habits. He was late with toilet training for bowel movements until 8 years of age related to his anxiety. At 10 years of age he was diagnosed with multiple behavior and emotional problems including depression and anxiety, which is contributing to his selective mutism. At the time of the evaluation at 13 years of age he was started on fluoxetine initially, then later citalopram. Eventually he was started on sertraline and aripiprazole to improve his mood and anxiety.

His issues with depression, anxiety, and selective mutism have continued from childhood into adulthood. Even with language and cognitive therapy in conjunction with pharmacological interventions, his behavior showed minimal improvement.

The patient was seen in the MIND Institute, UC Davis Medical Center at age 13, 18, and 26 years old. He demonstrates poor eye contact, some sensory issues, shyness, and social anxiety during assessments. The Autism Diagnostic Observation Schedule (ADOS) model 3 was done at 13 years of age and he received a score of 12, which falls in the autism spectrum disorder range.

His Vineland Adaptive Behavior Scales (VABS) score at 13 years of age was 74, with communication at 77, daily living skills at 81 and socialization at 71. These test results confer an adaptive level that is moderately low. He was also assessed with the Wechsler Intelligence Scale for Children-IV (WISC-IV) at age 13, but because of his oppositional behavior, testing results were limited. His score included two subtests with estimated scores of 53 for perceptual reasoning index (PRI) and 56 for processing speed.
The Wechsler Adult Intelligence Scale (WAIS-IV) was performed at 18 years of age showing a full-scale IQ of 64. Table 1 summarizes the cognitive assessment results.

The psychiatric evaluation was performed at 26 years of age using Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS). The K-SADS confirmed the previous impression of social anxiety disorder and oppositional defiant disorder (subthreshold) in addition to agoraphobia disorder and selective mutism. He did not meet the diagnosis of Autism. Per mother, the patient is described as having anxiety issues in new situations, refusing to cooperate, obstinacy, anger issues, and “shutting down” when communicating with new people. His anxiety and depressed mood became apparent at around 10 years of age when he began 5th grade in a public school. At that time, he had become self-destructive and would threaten self-harm. His mood improved after starting a school that catered to children with special needs.

His magnetic resonance imaging (MRI) scans acquired at 26 years of age show enlarged lateral ventricles, increased frontal subarachnoid spaces, disproportionally large hippocampal head (bilateral), and hypergyrification (i.e., complex cortical folding) (Figure 1). To confirm these observations, Z scores of the volumes of the four ventricles and whole brain and local gyration indices (LGI) of 68 cortical areas were computed relative to 8 age-matched healthy males (age mean 25.9 years, SD 1.27 years, range 24–28 years). The volumetric data were obtained using Brain GPS (Mori et al., 2016; Tang et al., 2013; Wang et al., 2013) followed by machine-learning based error correction and manual editing (Wang et al., 2011; Wang, Ngo, Hessl, Hagerman, & Rivera, 2016). LGI (Schaer et al., 2008) a measure of gyration by the ratio of total surface area (both hidden within the sulci and exposed on the outer surface of the brain) and exposed surface area was quantified using Freesurfer (Dale, Fischl, & Sereno, 1999; Fischl, Sereno, & Dale, 1999). While the volumes of 3rd and 4th ventricles were in the normal range (3rd/4th Z = −0.91/0.45, 63.7%/65.3%), lateral ventricles were 2.2-fold enlarged (35.2 ml, Z = 4.09, 0.0043%) and normalized whole brain volume was slightly reduced (1.51 L, Z = −1.90, 94.3%). In addition, he showed significantly increased LGI in the areas important for sensorimotor, auditory, language, and memory functions (Z = 2.28–5.00, 0.0001%–2.26%).

TABLE 1 Comparing cognitive assessment from 2006 and 2011

| Items                  | 2006 WISC-IV | 2011 WAIS-IV |
|------------------------|--------------|--------------|
| Verbal Comprehension   | N/A          | 63           |
| Perceptual Reasoning   | 53           | 80           |
| Working Memory         | N/A          | 65           |
| Processing Speed       | 56           | 66           |
| Verbal IQ              | 62           |              |
| Performance IQ         | 74           |              |
| Full Scale IQ          | 64           |              |

Note: Results given in Standard Score (Mean 100, SD 15)
3 | DISCUSSION

This case is an example of a premutation carrier with psychiatric and cognitive features that can be seen in premutation carriers with FXAND. These problems are significantly different from that of FXPOI and FXTAS, the other well-known premutation disorders. The patient did not meet the criteria of FXTAS because he did not experience tremor/ataxia, nor did he have MRI findings found in FXTAS. This presentation is unusual for a carrier with only 56 repeats and FMR1 mRNA at twice normal levels.

Extensive molecular and mitochondrial studies have already demonstrated an association with psychiatric disorders and premutation carrier status (Hagerman & Hagerman, 2016; Song et al., 2016) and that they can occur before neurological problems develop in FXTAS (Hall et al., 2016). The most common psychiatric problems seen in young boys with the premutation is anxiety (Cordeiro, Abucayan, Hagerman, Tassone, & Hessel, 2015). Cordeiro et al. (2015) studied 35 premutation carriers with the standardized Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV). They demonstrated that children and adult fragile X premutation carriers are at a higher risk for anxiety disorders, including Generalized Anxiety Disorder, Specific Phobia, Social Phobia and Obsessive-Compulsive Disorder than the general population. This patient presented with psychiatric problems typical in young premutation carriers, particularly with boys having a higher incidence of ASD (Farzin et al., 2006; Seritan, A., Ortigas, M., Seritan, S., A. Bourgeois, J., & J. Hagerman, R., 2013; Chonchaiya et al., 2012). The rates of ASD range from 8% to 73% depending on whether they presented through cascade testing or as a proband for their family (Farzin et al., 2006; Chonchaiya et al., 2012).

The severity of the anxiety disorder has been shown to correlate with the presence of ASD in male carriers which is consistent with this case study (Cordeiro et al., 2015). Other environmental exposures or “background” genetic modifiers likely effect the presentation of clinical manifestations in carriers (Muzar, Adams, Schneider, Hagerman, & Lozano, 2014). Chonchaiya et al. (2012) demonstrated that seizures in males with the premutation are associated with a higher rate of ASD, although our patient did not have clinical seizures.

MRI findings found in this patient were consistent with his clinical symptoms and with previous documentation of structural changes that can begin in childhood of premutation carriers (Wang et al., 2017). The enlarged lateral ventricles and increased frontal subarachnoid spaces may be related to poor absorption of cerebrospinal fluid that would lead to fluid stagnation and sleep problems (Mortazavi et al., 2018; Ringstad et al., 2018). Disproportionally large hippocampal head and hypergyrification (especially in the primary sensorimotor and auditory cortices) may reflect defective embryonic neurodevelopment that have been shown in knock-in mouse model of the premutation and may be associated with developmental delay, tactile defensiveness, sound sensitive, selective mutism, depression, and anxiety (Cunningham et al., 2010).

Molent et al. (2017) demonstrated increased hypergyrification and reduce cortical thickness is associated with generalized anxiety disorder (GAD) in the general population, suggesting a neurodevelopmental origin. This study is the first report of hypergyrification in a premutation carrier. In animal studies, we know that migration of neurons is impacted by the premutation (Cunningham et al., 2010). These MRI findings may prove useful in tracking GAD in premutation carriers as well as the changes in cerebral morphology as these patients age and begin to develop other neurological symptoms.

Premutation carriers have shown large phenotypic variability, ranging from FXTAS (Hagerman & Hagerman, 2013), psychiatric disorders (Seritan et al., 2013) to neurodevelopmental disorders (Farzin et al., 2006). This underlies the importance of identifying FXAND as a separate group of premutation disorders which require further treatment studies. Patients with this disorder suffer from significant psychiatric issues that can occur during childhood before any symptoms of FXTAS. It is hypothesized that the RNA toxicity and mitochondrial dysfunction that occurs in FXTAS may also be the pathogenesis of FXAND, but further studies are needed. It is also possible that this patient has additional genetic mutations that further led to his symptoms, but further studies of his genome are necessary to confirm this hypothesis.

ACKNOWLEDGMENTS

This research was funded by NICHD grant HD036071. In addition, support from the UC Davis MIND Institute Intellectual and Developmental Disabilities Research Center was funded by NICHD U54 HD079125.

CONFLICT OF INTEREST STATEMENT

Randi Hagerman has received funding from Zyenrba and Ovid for carrying out treatment studies in patients with fragile X syndrome. She has also consulted with Fulcrum, Ovid and Zyenrba regarding treatment studies in individuals with fragile X syndrome. Dr. Tassone has received funding from Zyenrba and Asuragen, Inc. The other authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

E.S., C.E., J.Y.W., and R.H. wrote the original draft along with reviewing and editing the manuscript. F.T., P.H., and R.H. conceived and presented the ideas. E.S. and C.E. contributed in data curation. J.Y.W., A.S., P.H., and R.H. contributed in data collection and lead the investigation, and formal analysis. F.T., A.S., J.Y.W., and P.H. analyzed and interpreted the data. All contributing authors had final approval of the version to be published.
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

REFERENCES

Bailey, D. B., Raspa, M., Olmsted, M., & Holiday, D. B. (2008). Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. *American Journal of Medical Genetics Part A*, 146A(16), 2060–2069. https://doi.org/10.1002/ajmg.a.32439

Chen, Y., Tassone, F., Berman, R. F., Hagerman, P. J., Hagerman, R. J., Willemsen, R., & Pessah, I. N. (2009). Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. *Human Molecular Genetics*, 19(1), 196–208. https://doi.org/10.1093/hmg/ddp479

Chonchaiya, W., Au, J., Schneider, A., Hessl, D., Harris, S. W., Laird, M..., Hagerman, P. J., Hagerman, R. J., Conde, V., Palomar, F. J., Lama, M. J., Martínez, R., Carrillo, F., Fischl, B., Sereno, M. I., & Dale, A. M. (1999). Cortical surface-based analysis. *NeuroImage*, 9(1), 1315–1322. https://doi.org/10.1006/nimg.1998.0396

Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. *American Journal of Medical Genetics Part A*, 146A(16), 2060–2069. https://doi.org/10.1002/ajmg.a.32439

Chen, Y., Tassone, F., Berman, R. F., Hagerman, P. J., Hagerman, R. J., Willemsen, R., & Pessah, I. N. (2009). Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. *Human Molecular Genetics*, 19(1), 196–208. https://doi.org/10.1093/hmg/ddp479

Chonchaiya, W., Au, J., Schneider, A., Hessl, D., Harris, S. W., Laird, M., ... Hagerman, R. J. (2012). Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. *Human Genetics*, 131(4), 581–589. https://doi.org/10.1007/s00439-011-1106-6

Conde, V., Palomar, F. J., Lama, M. J., Martínez, R., Carrillo, F., Pintado, E., & Mir, P. (2013). Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation. *Journal of Neurophysiology*, 109(5), 1315–1322. https://doi.org/10.1152/jn.00730.2012

Cordeiro, L., Abucayan, F., Hagerman, R., Tassone, F., & Hessl, D. (2015). Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. *Intractable & Rare Disease Research*, 4(3), 123–130. https://doi.org/10.5582/irdr.2015.01029

Cunningham, C. L., Martínez Cerdeño, V., Navarro Porras, E., Prakash, A. N., Angelastro, J. M., Willemsen, R., ... Noctor, S. C. (2010). Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. *Human Molecular Genetics*, 20(1), 64–79. https://doi.org/10.1093/hmg/ddq432

Dale, A. M., Fischl, B., & Sereno, M. I. (1999). Cortical surface-based analysis. *NeuroImage*, 9(2), 179–194. https://doi.org/10.1006/nimg.1998.0395

D’Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006). Decreased expression of the Fmr1 gene in patients with the fragile X syndrome. *Human Molecular Genetics*, 15(12), 2384–2391. https://doi.org/10.1093/hmg/ddp479

Fischl, B., Sereno, M. I., & Dale, A. M. (1999). Cortical surface-based analysis. *NeuroImage*, 9(2), 195–207. https://doi.org/10.1006/nimg.1998.0396
of antioxidants in precision medicine. *Molecular Medicine*, 22(1), 548–559. https://doi.org/10.2119/molmed.2016.00122

Tang, X., Oishi, K., Faria, A. V., Hillis, A. E., Albert, M. S., Mori, S., & Miller, M. I. (2013). Bayesian parameter estimation and segmentation in the multi-atlas random orbit model. *PLoS ONE*, 8(6), https://doi.org/10.1371/journal.pone.0065591

Tassone, F., Greco, C. M., Hunsaker, M. R., Seritan, A. L., Berman, R. F., Gane, L. W., … Hagerman, R. J. (2012). Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. *Genes, Brain and Behavior*, 11(5), 577–585. https://doi.org/10.1111/j.1601-183x.2012.00779.x

Wang, H., Das, S. R., Suh, J. W., Altinay, M., Pluta, J., Craige, C., … Yushkevich, P. A. (2011). A learning-based wrapper method to correct systematic errors in automatic image segmentation: Consistently improved performance in hippocampus, cortex and brain segmentation. *NeuroImage*, 55(3), 968–985. https://doi.org/10.1016/j.neuroimage.2011.01.006

Wang, H., Pouch, A., Takabe, M., Jackson, B., Gorman, J., Gorman, R., & Yushkevich, P. A. (2013). Multi-atlas segmentation with robust label transfer and label fusion. *Information processing in medical imaging: proceedings of the conference*, 23, 548–559. https://doi.org/10.1007/978-3-642-38868-2_46

Wang, J. Y., Hessl, D., Hagerman, R. J., Simon, T. J., Tassone, F., Ferrer, E., & Rivera, S. M. (2017). Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation. *Neurobiology of Aging*, 55, 11–19. https://doi.org/10.1016/j.neurobiaging.2017.03.018

Wang, J. Y., Ngo, M. M., Hessl, D., Hagerman, R. J., & Rivera, S. M. (2016). Robust Machine Learning-Based Correction on Automatic Segmentation of the Cerebellum and Brainstem. *PLoS ONE*, 11(5), https://doi.org/10.1371/journal.pone.0156123

**How to cite this article:** Santos E, Emeka-Nwonovo C, Wang JY, et al. Developmental aspects of FXAND in a man with the FMR1 premutation. *Mol Genet Genomic Med*. 2020;8:e1050. https://doi.org/10.1002/mgg3.1050